Literature DB >> 8742561

Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial.

.   

Abstract

OBJECTIVE: To evaluate the effect of intensive diabetes treatment on patient quality of life assessed by the Diabetes Quality-of-Life Measure, the Symptom Checklist-90R, the Medical Outcome Study 36-Item Short Form Survey, and intercurrent psychosocial events in the Diabetes Control and Complications Trial (DCCT). RESEARCH DESIGN AND METHODS: The DCCT was a 29-center prospective controlled clinical trial that demonstrated the beneficial effect of intensive diabetes treatment on retinopathy, nephropathy, and neuropathy. The 1,441 volunteers with IDDM, aged 13-39 years, were randomly assigned to intensive or conventional diabetes therapy. The volunteers were followed for a mean of 6.5 years (range 3-9 years). Quality-of-life data were collected during annual visits. Of the volunteers, 99% completed the study, and > 95% of scheduled tests were completed.
RESULTS: All analyses of quality of life, psychiatric symptom indexes, and psychosocial event data showed no differences between intensive and conventional diabetes treatment.
CONCLUSION: Under careful treatment conditions, such as those followed in the DCCT, patients undergoing intensive diabetes treatment do not face deterioration in the quality of their lives, even while the rigor of their diabetes care is increased.

Entities:  

Mesh:

Year:  1996        PMID: 8742561     DOI: 10.2337/diacare.19.3.195

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  70 in total

Review 1.  Clinical evidence: glycaemic control in diabetes.

Authors:  W H Herman
Journal:  BMJ       Date:  1999-07-10

2.  Quality of life among diabetic patients in Swedish primary health care and in the general population: comparison between 1992 and 1995.

Authors:  P E Wändell; B Brorsson; H Aberg
Journal:  Qual Life Res       Date:  1998-12       Impact factor: 4.147

3.  Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications.

Authors:  J Hahl; H Hämäläinen; H Sintonen; T Simell; S Arinen; O Simell
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

4.  Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes.

Authors:  Sheri L Maddigan; David H Feeny; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

5.  Reliability and validity of the Norwegian child and parent versions of the DISABKIDS Chronic Generic Module (DCGM-37) and Diabetes-Specific Module (DSM-10).

Authors:  Dag Helge Frøisland; Trond Markestad; Tore Wentzel-Larsen; Torild Skrivarhaug; Knut Dahl-Jørgensen; Marit Graue
Journal:  Health Qual Life Outcomes       Date:  2012-02-02       Impact factor: 3.186

6.  Health-related quality of life and quality of life in type 2 diabetes: relationships in a cross-sectional study.

Authors:  Murali Sundaram; Jan Kavookjian; Julie Hicks Patrick
Journal:  Patient       Date:  2009-06-01       Impact factor: 3.883

7.  Mediators of depressive symptoms in children with type 1 diabetes and their mothers.

Authors:  Sarah S Jaser; Robin Whittemore; Jodie M Ambrosino; Evie Lindemann; Margaret Grey
Journal:  J Pediatr Psychol       Date:  2007-11-08

Review 8.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

9.  HRQOL in Diverse Ethnic Groups with Diabetes: Findings from the 2014 BRFSS.

Authors:  Kelley Newlin Lew; Julie Wagner; Omar Braizat
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-14

10.  Long-term effect of diabetes and its treatment on cognitive function.

Authors:  Alan M Jacobson; Gail Musen; Christopher M Ryan; Nancy Silvers; Patricia Cleary; Barbara Waberski; Amanda Burwood; Katie Weinger; Meg Bayless; William Dahms; Judith Harth
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.